Routine ESOP grant with no immediate trading implications. Monitor next quarterly filing for potential modest dilution impact from option exercises, though 3-year vesting makes this a distant consideration.
RDY drugs
RDY drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 11 $13.14entry
- T+1 · 6mo ago −5.17%α −5.04% · $12.46
- T+5 · 6mo ago +3.50%α +3.59% · $13.60
- T+20 · 5mo ago +1.75%α +2.05% · $13.37
- T+60 · 3mo ago −7.61%α −12.00% · $12.14
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Dr. Reddy's granted 1,192,234 stock options (816,119 Indian stock options + 376,115 ADR stock options) to eligible employees under existing ESOP schemes at an exercise price of Rs. 1,293.90 per share. This is a routine employee compensation event with no material financial impact or strategic significance.
Key Facts
- Grant of 816,119 Indian stock options under Dr. Reddy's Employees Stock Option Scheme, 2018
- Grant of 376,115 ADR stock options under Dr. Reddy's Employees ADR Stock Option Scheme, 2007
- Exercise price of Rs. 1,293.90 per share for both tranches
- 100% vesting at the end of 3 years for both option types
- Approved by Nomination, Governance and Compensation Committee on May 11, 2026
Financial Impact
No material financial impact, standard employee stock compensation grant with 3-year vesting; dilution is minimal relative to total shares outstanding
Risk Factors
- Minimal dilution risk from eventual option exercises over 3-year vesting period
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001575872-26-000280 |
| Document: 0001575872-26-000280-index.html | 0001575872-26-000280 |
| Document: 0001575872-26-000280.txt | 0001575872-26-000280 |
Track record
73 reports on RDY
7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 7 of 12 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
- Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
- Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
- Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
- Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
- Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
- Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers